Table 1.
Patient characteristic in MIMIC cohort.
| Variables | Total n = 3044 | PLT < 100 × 109/L n = 838 | PLT ≥ 100 × 109/L n = 2206 | P |
|---|---|---|---|---|
| Age, median [IOR] | 68.6 [56.5;79.3] | 67.0 [55.1;78.3] | 69.2 [56.9;79.6] | 0.002 |
| Gender | 0.710 | |||
| Male, n (%) | 1718 (56.4) | 478 (57.0) | 1240 (56.2) | |
| Female, n (%) | 1326 (43.6) | 360 (43.0) | 966 (43.8) | |
| Medical conditions | ||||
| Myocardial infarct, n (%) | 458 (15.0) | 139 (16.6) | 319 (14.5) | 0.159 |
| Congestive heart failure, n (%) | 961 (31.6) | 258 (30.8) | 703 (31.9) | 0.597 |
| Chronic pulmonary disease, n (%) | 727 (23.9) | 188 (22.4) | 539 (24.4) | 0.268 |
| Mild liver disease, n (%) | 414 (13.6) | 198 (23.6) | 216 (9.79) | <0.001 |
| Diabetes, n (%) | 958 (31.5) | 232 (27.7) | 726 (32.9) | 0.006 |
| Renal disease, n (%) | 541 (17.8) | 132 (15.8) | 409 (18.5) | 0.108 |
| Malignant cancer, n (%) | 373 (12.3) | 127 (15.2) | 246 (11.2) | 0.003 |
| CCI, median [IQR] | 5 [4;7] | 5 [4;7] | 5 [4;7] | 0.144 |
| Primary infection source | ||||
| Lung, n (%) | 1077 (35.4) | 316 (37.7) | 761 (34.5) | 0.107 |
| Abdomen, n (%) | 1089 (35.8) | 328 (39.1) | 761 (34.5) | 0.019 |
| Urinary, n (%) | 641 (21.1) | 184 (22.0) | 457 (20.7) | 0.484 |
| Skin and soft tissue, n (%) | 128 (4.20) | 43 (5.13) | 85 (3.85) | 0.142 |
| Central nervous system, n (%) | 52 (1.71) | 13 (1.55) | 39 (1.77) | 0.798 |
| Endocardium, n (%) | 207 (6.80) | 66 (7.88) | 141 (6.39) | 0.170 |
| Intravascular devices, n (%) | 332 (10.9) | 79 (9.43) | 253 (11.5) | 0.121 |
| other, n (%) | 130 (4.0) | 30 (3.1) | 100 (4.3) | 0.116 |
| Unknown, n (%) | 242 (7.95) | 70 (8.35) | 172 (7.80) | 0.666 |
| Lab value (median [IQR]) | ||||
| WBC, ×109/L | 12.8 [8.6;19.4] | 9.9 [6.8;17.6] | 13.7 [9.1;20] | <0.001 |
| PT, second | 15.9[14.1;20.2] | 17.6[15.1;23.5] | 15.4[13.9;18.9] | <0.001 |
| INR | 1.4 [1.2,1.8] | 1.5 [1.3,2.0] | 1.3 [1.2,1.7] | <0.001 |
| APTT, second | 37.5 [30.7;59.1] | 43.6[33.6;70.5] | 35.7 [29.9;53.0] | <0.001 |
| Bilirubin, mg/dl | 1.0 [0.5;2.3] | 1.8 [0.9;4.3] | 0.8 [0.5;1.6] | <0.001 |
| Creatinine, mg/dl | 1.5 [1.0;2.3] | 1.7 [1.2;2.9] | 1.3 [0.9;2.1] | <0.001 |
| Lactate, mmol/L | 2.1 [1.4;3.3] | 2.8 [1.9;4.9] | 1.9 [1.3;2.9] | <0.001 |
| Microorganism | 0.003 | |||
| Bacteroides Fragilis species, n (%) | 88 (2.89) | 18 (2.1) | 70 (3.2) | |
| β Streptococcus species, n (%) | 135 (4.43) | 38 (4.5) | 97 (4.4) | |
| Candida species, n (%) | 220 (7.23) | 76 (9.1) | 144 (6.5) | |
| Enterobacter species, n (%) | 81 (2.66) | 27 (3.2) | 54 (2.4) | |
| Enterococcus species, n (%) | 318 (10.45) | 65 (7.8) | 253 (11.5) | |
| Escherichia species, n (%) | 728 (23.91) | 224 (26.7) | 504 (22.8) | |
| Klebsiella species, n (%) | 273 (8.97) | 80 (9.5) | 193 (8.7) | |
| Proteus species, n (%) | 61 (2.00) | 15 (1.8) | 46 (2.1) | |
| Pseudomonas species, n (%) | 92 (3.02) | 26 (3.1) | 66 (3.0) | |
| Serratia species, n (%) | 65 (2.13) | 23 (2.7) | 42 (1.9) | |
| Staphylococcus species, n (%) | 906 (29.76) | 231 (27.6) | 675 (30.6) | |
| Streptococcus Pneumoniae, n (%) | 77 (2.53) | 15 (1.8) | 62 (2.8) | |
| SAPS II, median [IQR] | 38 [30;49] | 42[34;54] | 37[29;47] | <0.001 |
| SOFA score, median [IQR] | 7 [5,10] | 10 [7,13] | 6 [4,8] | <0.001 |
| Septic Shock, n (%) | 2032 (66.8) | 654 (78.0) | 1378 (62.5) | <0.001 |
| Vasopressor usage, n (%) | 1466 (48.2) | 553 (66.0) | 913 (41.4) | <0.001 |
| Mechanical Ventilation usage, n (%) | 1404 (46.1) | 482 (57.5) | 922 (41.8) | <0.001 |
| Extra-corporeal epuration, n (%) | 180 (5.91) | 54 (6.44) | 126 (5.71) | 0.497 |
| Anti-platelet drugs | 958(31.5) | 204 (24.3) | 754 (34.2) | <0.001 |
| Mortality | ||||
| 28-day death, n (%) | 517 (17.0) | 225 (26.8) | 292 (13.2) | <0.001 |
| In hospital death, n (%) | 487 (16.0) | 227 (27.1) | 260 (11.8) | <0.001 |
Date expressed as median(Q1-Q3) or number (percentage). PLT, Platelet; CCI, Charlson comorbidity index; WBC, White blood cells; PT, prothrombin time; INR, International normalized ratio; APTT, activated partial thromboplatin time; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment score.